Cytos Biotechnology Ltd said that it is reclaiming a vaccine asset that had been licensed to Novartis for the treatment of nicotine addiction following the failure of a Phase 2 trial. The product is a therapeutic vaccine. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
